A Comprehensive Monograph on Aclidinium Bromide: Pharmacology, Clinical Efficacy, and Therapeutic Profile

Section 1: Drug Identity and Physicochemical Properties

1.1. Nomenclature and Identifiers

Aclidinium bromide is a small molecule pharmaceutical agent classified as a long-acting muscarinic antagonist (LAMA), a subclass of anticholinergic bronchodilators.[1] Its chemical identity is precisely defined by a comprehensive set of internationally recognized identifiers, which are essential for its unambiguous reference in clinical, regulatory, and research contexts.

The International Nonproprietary Name (INN) for the active substance is Aclidinium Bromide.[2] Chemically, it is a quaternary ammonium ion and a carboxylic ester, structurally characterized as a member of thiophenes and an aromatic ether, functionally related to 3-quinuclidinol.[1] For database and informatics purposes, it is assigned DrugBank ID DB08897 [1], ChEBI ID CHEBI:65346 [1], and ChEMBL ID CHEMBL1194325.[1]

A point of potential confusion is the existence of two primary CAS Numbers associated with the substance. The CAS Number 727649-81-2 refers to the aclidinium cation itself, while 320345-99-1 is often used for the bromide salt form in which the drug is formulated and administered.[1] Its IUPAC name is formally stated as-1-azoniabicyclo[2.2.2]octan-8-yl] 2-hydroxy-2,2-di(thiophen-2-yl)acetate or, more completely for the salt,octan-3-yl] 2-hydroxy-2,2-dithiophen-2-ylacetate;bromide.[3]

Aclidinium bromide is marketed globally under several brand names. In the United States, it is known as Tudorza Pressair.[2] In the United Kingdom and other European Union member states, it is available as

Eklira Genuair.[2] The name

Bretaris Genuair is used in the majority of EU states where it is licensed to Menarini.[2] In Canada, it is marketed as